Abstract CT078: First-line Treatment with Sintilimab (sin) Vs Placebo in Combination with Chemotherapy (chemo) in Patients (pts) with Unresectable Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Final Overall Survival (OS) Results from the Randomized, Phase III ORIENT-16 Trial